Objective: To determine the immunologic characteristics of tumor infiltrating lymphocytes (TILs) in comparison with the corresponding peripheral blood lymphocytes (PBLs) of patients with overian cancer in order to detect specific antitumor-reactive-immunocompetent cells.
Methods: Tumor infiltrating lymphocytes and PBLs were phenotyped by their surface markers, cytokine pattern, proliferation rate, and cytotoxic ability.
Results: The phenotypes of both lymphocyte populations were very heterogeneous. Peripheral blood lymphocytes had a higher proliferative activity and cytotoxicity against natural killer-sensitive tumor cells than the coreesponding TILs. Furthermore TILs showed increased interleukin-4 expression whereas in PBLs, interferon-γ production predominated.
Conclusion: Peripheral blood lymphocytes showed more potentially valuable behavioral characteristics than TILs. in the future we need to combine several methods in order to define immune cells with antitumor activity. These cells should be expanded ex vivo and stimulated specifically for use in the immunotherapy of overian cancer.
1. Mallmann P, Krebs D. Generation and activation of tumorinfiltrating lymphocytes for lymphokine-activated killer cell therapy (LAK-TIL's Therapy) in patients with disseminated breast and ovarian cancer. Gynäkol Geburtshilfl Rundsch1995; 35(Suppl 1): 161-165.
2.
2. Freedman RS. Edwards CL, Kavangh JJ, et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-in-filtrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial. J Immunother Emphasis Tumor Immunol1994;16:198-210.
3.
3. Freedman RS, Platsoucas CD. Immunotherapy for peritoneal overian carcinoma metastasis using ex vivo expanded turnor infiltrating lymphocytes. Cancer Treat Res1996;82:115-146.
4.
4. Freedman RS, Tomasovic B, Templin S, et al. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Meth1994;167:145-160.
5.
5. Mallmann P. Autologous tumor-cell vaccination and lymphokine-activated tumor-infiltrating lymphocytes (LAK-TIL's). Hybridoma1993;12:559-566.
6.
6. Melioli G, Ratto GB, Ponte M. et al. Treatment of stage IIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J immunother Emphasis Tumor Immunol1996;19:224-230.
7.
7. Arienti F, Belli F, Rivoltini L, et al. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol Immunother1993;36:315-322.
8.
8. Kim HJ, Heo DS, Suh CI, Kim HT, Bang YJ, Kim NK. In vitro generation of immune effector cells from tumor-associated lymphocytes of human gastric cancer. Anticancer Res1995;15:1247-1256.
9.
9. Donnerstag B, Schröder W, Hoos P, Pltrogge JB, Trager L, Bender HG. Interactions between tumor cells and tumor infiltrating lymphocytes in human overian carcinoma. Clin Exp Obstet Gynecol1994;21:153-159.
10.
10. Bateman WJ, Donnellan I, Fraser IA, WOng LS, Morris AG. Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon-γ. Cancer Immunol Immunother1995;41:61-67.
11.
11. Facchetti P, Prigione I, Ghiotto F, Tasso P, Garaventa A, Pistoisa V. Functional and molecular characterization of tumour-infiltrating lympocytes and clones thereof from a major-histocompatibility complex-negative human tumour: Neuroblastoma. Cancer Immunol Immunother1996;42:170-178.
12.
12. Freedman RS, Ioannides CG, Mathioudakis G, Platsoucas CD, Novel immunologic strategies in ovarian carcinoma. Am J Obstet Gynecol1992;167:1470-1478.
13.
13. Elsässer-Beile U, Wetterauer U. Schultze-Seemann W, Gallati H, Schulte Mönting J, von Kleist S. Analysis of the immune reactivity of infiltrating and peripheral lymphocytes from patients with renal cell carcinoma by measuring cytokine secretion. Cancer Immunol Immunother1996;42:93-98.
14.
14. Coventry BJ, Weeks SC, Heckford SE, Sykes PJ, Bradley J, Skinner JM, Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma. J immunol1996;156:3486-3492.
15.
15. Karimine N, Nanbara S, Arinaga S, Asoh T, Ueo H, Akiyoshi T. Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients. J Surg Oncol1994;55:179-185.
16.
16. Schöndorf T, Engel H, Lindemann C, Kolhagen H, von Rücker AA, Mallmann P. Cellular characteristics of peripheral blood hymphocytes and tumor infiltrating lymphocytes in patients with gynaecological tumors. Cancer Immunol Immunother1997;44:88-96.
17.
17. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: cretion. J Immunother1992;12:1-12.
18.
18. Yanelli JR, Hyatt C, McConnell S, et al. Growth of tumorinfiltrating lymphocytes from human solid cancers: Summar of tumorinfiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. Int J Cancer1996;65:413-421.
19.
19. Young MRI, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer: Influence on the imune infiltrate of the cancer. Int J Cancer1996;67:333-338.
20.
20. Dadmarz R, Sgagias MK, Rosenberg SA, Schwartzentruber DJ. CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol Immunother1995;40:1-9.
21.
21. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp immunol1996;105:355-352.
23. Lee KY, Goedegebuure PS, Linehan DC, Ederlein TJ. Immunoregulatory effects of CD4+ T helper subsets in human melanoma. Surgery1995;117:365-372.
24.
24. Plaisance S, Rubinstein E, Alileche A, et al. Human melanoma cells express a functional interleukin-2 receptor. Int J Cancer1993;55:164-170.
25.
25. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD, Freeman SM. Tumor-host interaction: Analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol1997;28:321-331.
26.
26. Alexander JP, Kudoh S, Melsop KA, et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 reception. Cancer Res1993;53:1380-1387.
27.
27. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Scinece1992;258:1795-1798.
28.
28. McCoy JP Jr, Overton WR. Quality control in flow cytometry for diagnostic pathology: II. A conspectus of reference ranges for lymphocyte immunophenotyping. Cytometry1994;18:129-139.
29.
29. O'Garra A, Murphy K. Role of cytokines in development of Th1 and Th2 cells In: Romagnani S, ed. Th1 and Th2 cells in health and discase. Chemical lmmunology Volume 63. HBasel, Switzerland: Karger AG, 1996:1-13.
30.
30. Whiteside TL, Parmiani G. Tumor-infiltrating lymphocytes: Their phenotype, functions and clinical use. Cancer Immunol Immunother1994;39:15-21.
31.
31. Baxevanis CN, Dedoussis GVZ, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M. Tumor specific cytolysis by tumor infiltrating lymphocytes in breat cancer. Cancer1994;74:1275-1282.
32.
32. Mantovani G, Macciò A, Versace R, et al. Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. J Mol Med1995;73:409-416.
33.
33. Wang Q, Redovan C, Tubbs R, et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer1995;61:780-785.
34.
34. Kharkevitch DD, Seito D, Balch GC, Maeda T, Balch CM, Itoh K. Characterization of autologous tumor-specific T-helper 2 cells in tunor-infiltrating lymphocytes from a patient with metastatic melanoma. Int J Cancer1994;58:317-323.
35.
35. Camp BJ, Dyhrman ST, Memoli VA, Mott LA, Barth RJ Jr. In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oncol 1996;3:176-184.
36.
36. Vitolo D, Zerbe T, Kanbour A, Dahl C. Herberman RB, Whiteside TL. Expression of mRNA for cytokines in tumorinfiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer1992;51:573-580.
37.
37. Rabinowich H, Suminami Y, Reichert TE, et al. Expression of cytokine genes or proteins and signalling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer1996;68:276-284.
